Minneapolis-based NightWare — maker of a smartwatch therapeutic for people with nightmare disorder and PTSD-driven nightmares — has received breakthrough therapy designation for its in-development product. In addition, the company is launching two new placebo-controlled randomized clinical trials for its digital intervention, one of which is being conducted within Department of Veterans Affairs...
San Francisco-based Hinge Health has completed a randomized control trial of its digital care program for chronic knee pain. Results were promising, with users of the digital platform outperforming the control group in every outcome measure, though there was some loss of engagement among the study group.
“It was really strong results,” CEO Daniel Perez told MobiHealthNews. “It was a trial that...
A new overview of systematic reviews of published randomized control trials of mobile health apps found just 23 RCTs of currently-available apps have been conducted, and less than half of those showed a positive health effect from the app in question.
A group of researchers from the Centre for Research in Evidence-Based Practice at Bond University in Queensland, Australia conducted the review,...
New York City-based ProofPilot, a startup creating technology to help anyone launch a randomized control trial, has re-launched its clinical trial product.
The software-as-a-service product is available to academic and clinical researchers as well as individuals, non-profits, and community groups. There are a range of versions at different price points, with the lowest being free and the highest...
Wellness company Healthways, through its subsidiary MeYou Health, has completed a randomized control trial demonstrating that their own employees using their Walkadoo platform -- consisting of adaptable, tailored reminders -- and Fitlinxx Pebble activity trackers walked an average of 970 steps per day more than a control group with just the trackers.
Johns Hopkins physicians were also on the...
Bant: A diabetes management app
The role of evidence in mobile health app development -- and the level of scrutiny such apps should be subjected to -- is still an open question. At the mHealth Summit 2012, a variety of speakers from different sectors of the market offered their opinions on what, exactly, is meant by evidence and on the perennial question of the value of randomized controlled...
